Article

Repurposing CZC54252 to target EGFR C797S mutations and conquer Osimertinib resistance

2024-11-15

Abstract excerpt

Background and Purpose: EGFR targeted therapy has pioneered a new era of NSCLC treatment. However, drug resistance is the major challenge of such therapy. Osimertinib is the latest generation of EGFR inhibitor and is clinically used for the treatment of NSCLC patients harboring EGFR T790M gatekeeper mutations. Unfortunately, the patients treated with Osimertinib also developes resistance and no follow-up drugs ar...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2c815303-1669-5d99-badb-fc7e6ca96b38
DOI: 10.22541/au.173166683.37747041/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Repurposing CZC54252 to target EGFR C797S mutations and conquer Osimertinib resistanceDOI 10.22541/au.173166683.37747041/v1Read

CZC54252 overcomes Osimertinib resistance by targeting EGFRC797S mutations.Semantic proximity Read

Discovery of Potent and Wild-Type-Sparing Fourth-Generation EGFR Inhibitors for Treatment of Osimertinib-Resistance NSCLC.Semantic proximity Read

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.Semantic proximity Read

Design, synthesis, and antitumor activity evaluation of potent fourth-generation EGFR inhibitors for treatment of Osimertinib resistant non-small cell lung cancer (NSCLC).Semantic proximity Read

Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry.Semantic proximity Read

Modification of osimertinib to discover new potent EGFRC797S-TK inhibitors.Semantic proximity Read

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.Semantic proximity Read

Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?Semantic proximity Read

Discovery of Novel Fourth-Generation EGFR Inhibitors to Overcome C797S-Mediated Resistance.Semantic proximity Read

Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer.Semantic proximity Read

EGFR G796D mutation mediates resistance to osimertinib.Semantic proximity Read